Primary 4T1 tumor resection provides critical "window of opportunity" for immunotherapy

Anahit Ghochikyan1, Arpine Davtyan, Armine Hovakimyan

  • 1Department of Molecular Immunology, Institute for Molecular Medicine, 16371 Gothard Street, Suite H, Huntington Beach, CA, 92647, USA, aghochikyan@immed.org.

Related Concept Videos